Search

Displaying results 5681 - 5690 of 10000 in total
  1. Drug

    Levosemotiadil

    go.drugbank.com/drugs/DB20446
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Levosemotiadil is a vasodilator. Levosemotiadil has a monoisotopic molecular weight of 536.2 Da.

  2. Drug

    Ipramidil

    go.drugbank.com/drugs/DB20454
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Ipramidil is a vasodilator. Ipramidil has a monoisotopic molecular weight of 256.12 Da.

  3. Drug

    Belfosdil

    go.drugbank.com/drugs/DB21327
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Belfosdil is a vasodilator. Belfosdil has a monoisotopic molecular weight of 548.3 Da.

  4. Drug

    Litomeglovir

    go.drugbank.com/drugs/DB21363
    Experimental

    The usage of the INN stem '-vir' in the name indicates that Litomeglovir is a antiviral. Litomeglovir has a monoisotopic molecular weight of 498.19 Da.

  5. Drug

    Norgesterone

    go.drugbank.com/drugs/DB21409
    Experimental

    The usage of the INN stem '-terone' in the name indicates that Norgesterone is a antiandrogen. Norgesterone has a monoisotopic molecular weight of 300.21 Da.

  6. Drug

    Pitenodil

    go.drugbank.com/drugs/DB21442
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Pitenodil is a vasodilator. Pitenodil has a monoisotopic molecular weight of 353.18 Da.

  7. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10596
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10600
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10776
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen